Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01676
|
|||||
| Drug Name |
Epothilone A
|
|||||
| Synonyms |
Epothilone A; (-)-Epothilone A; Epo A; epothile; Epothilone-A; UNII-51E07YBX96; Epoa; 51E07YBX96; EP; Epothilones; Epothilon A; (1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12-tetramethyl-3-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione; 4,17-Dioxabicyclo[14.1.0]heptadecane-5,9-dione,7,11-dihydroxy-8,8,10,12-tetramethyl-3-[(1E)-1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-,(1S,3S,7S,10R,11S,12S,16R)-
|
|||||
| Indication | Cancer [ICD11: 2A00-2F9Z] | Preclinical | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C26H39NO6S
|
|||||
| Canonical SMILES |
CC1CCCC2C(O2)CC(OC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC3=CSC(=N3)C)C
|
|||||
| InChI |
InChI=1S/C26H39NO6S/c1-14-8-7-9-19-21(32-19)11-20(15(2)10-18-13-34-17(4)27-18)33-23(29)12-22(28)26(5,6)25(31)16(3)24(14)30/h10,13-14,16,19-22,24,28,30H,7-9,11-12H2,1-6H3/b15-10+/t14-,16+,19+,20-,21-,22-,24-/m0/s1
|
|||||
| InChIKey |
HESCAJZNRMSMJG-KKQRBIROSA-N
|
|||||
| CAS Number |
CAS 152044-53-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 493.7 | Topological Polar Surface Area | 138 | ||
| Heavy Atom Count | 34 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
4
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:31549
|
|||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Epothilone A-an overview | |||||
| 2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.